Determination of HU override for gold fiducial markers in proton therapy

Documenti analoghi

• Application of intrahepatic fiducial markers in carbon ion radiotherapy for pancreatic cancer—Achieving higher precision treatment
  di: Junya Nagata, et al.
  Pubblicazione: (2025)
• Intra‐ and inter‐fractional variations of tumors with fiducial markers measured using respiratory‐correlated computed tomography images for respiratory gated lung stereotactic body radiation therapy
  di: Yuki Manabe, et al.
  Pubblicazione: (2024)
• Distance‐based assessment of spatial artifact extension in the prostate from fiducial markers in diffusion‐weighted magnetic resonance imaging
  di: Mizgin Coskun, et al.
  Pubblicazione: (2025)
• Dosimetric and biological impact of activity extravasation of radiopharmaceuticals in PET imaging
  di: Ashok Tiwari, et al.
  Pubblicazione: (2024)
• Hypoxia‐informed RBE‐weighted beam orientation optimization for intensity modulated proton therapy
  di: Pavitra Ramesh, et al.
  Pubblicazione: (2024)